The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Merck; Tyme
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Cardinal Health; Eisai; Janssen; Novartis; Pfizer; Seagen
Speakers' Bureau - Sanofi
Research Funding - Eisai; NCI; Prostate Cancer Foundation
A phase II study of lenvatinib plus everolimus in patients with advanced non-clear cell renal cell carcinoma (nccRCC).
 
Thomas E. Hutson
Employment - Texas Oncology
Honoraria - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Consulting or Advisory Role - Astellas Pharma; Bayer/Onyx; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Novartis; Pfizer
Speakers' Bureau - Astellas Pharma; Bristol-Myers Squibb; Eisai; Exelixis; Johnson & Johnson; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Johnson & Johnson (Inst); Pfizer (Inst)
 
M Dror Michaelson
Employment - Cullinan Oncology (I); Jounce Therapeutics (I)
Stock and Other Ownership Interests - Jounce Therapeutics (I)
Honoraria - Exelixis; Novartis; Pfizer
Consulting or Advisory Role - Exelixis; Novartis; Pfizer
Research Funding - Eisai (Inst); Exelixis (Inst); Millennium (Inst); Pfizer (Inst)
 
Timothy M. Kuzel
No Relationships to Disclose
 
Neeraj Agarwal
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; AstraZeneca; Bayer; Bristol-Myers Squibb; Exelixis; Foundation Medicine; Foundation One Inc; Lilly; Lilly; Medivation/Astellas; Nektar; Pfizer; Pharmacyclics
Research Funding - Active Biotech (Inst); Amgen (Inst); AstraZeneca (Inst); Bavarian Nordic (Inst); Bayer (Inst); BN ImmunoTherapeutics (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celldex (Inst); Eisai (Inst); Exelixis (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Immunomedics (Inst); Janssen (Inst); Merck (Inst); Newlink Genetics (Inst); Novartis (Inst); Pfizer (Inst); Prometheus (Inst); Rexahn Pharmaceuticals (Inst); Sanofi (Inst); Takeda (Inst); TRACON Pharma (Inst)
 
Ana M. Molina
Honoraria - ASCO
Consulting or Advisory Role - Eisai; Exelixis; Janssen; Novartis
 
James J Hsieh
Honoraria - Chugai Pharma
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis
Research Funding - CGI; Eisai; Novartis; Pfizer
 
Ulka N. Vaishampayan
Honoraria - Bayer; Bristol-Myers Squibb; Exelixis; Pfizer; Sanofi
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; EMD Serono; Exelixis; Pfizer
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Eisai; Exelixis; Pfizer; Sanofi
Research Funding - Astellas Pharma; Bristol-Myers Squibb; Exelixis; Pfizer
 
Sharon Xie
Employment - Eisai
 
Urmi Bapat
Employment - Eisai
Stock and Other Ownership Interests - Bristol-Myers Squibb
Honoraria - Boston Scientific; Medtronic
Consulting or Advisory Role - Boston Scientific; Medtronic
 
Rohit K. Jain
Honoraria - Alphasights (I); Dava Oncology
Consulting or Advisory Role - Taiho Pharmaceutical (I)
 
Mayer N. Fishman
Consulting or Advisory Role - Novartis; Pfizer; Pfizer
Speakers' Bureau - Exelixis; Ipsen; Medivation
Research Funding - Acceleron Pharma (Inst); Alkermes (Inst); Argos Therapeutics (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); Merck (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Prometheus (Inst)